开源亲电片段筛选平台确定UCHL1共价抑制剂的化学起点。

IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS SLAS Discovery Pub Date : 2024-12-01 DOI:10.1016/j.slasd.2024.100198
Scott B. Ficarro , Zachary H. Marto , Nicholas M. Girardi , Dingyu Deng , Isabella Jaen Maisonet , Guillaume Adelmant , Laura E. Fleming , Mona Sharafi , Isidoro Tavares , Andrew Zhao , HyoJeon Kim , Hyuk-Soo Seo , Sirano Dhe-Paganon , Sara J. Buhrlage , Jarrod A. Marto
{"title":"开源亲电片段筛选平台确定UCHL1共价抑制剂的化学起点。","authors":"Scott B. Ficarro ,&nbsp;Zachary H. Marto ,&nbsp;Nicholas M. Girardi ,&nbsp;Dingyu Deng ,&nbsp;Isabella Jaen Maisonet ,&nbsp;Guillaume Adelmant ,&nbsp;Laura E. Fleming ,&nbsp;Mona Sharafi ,&nbsp;Isidoro Tavares ,&nbsp;Andrew Zhao ,&nbsp;HyoJeon Kim ,&nbsp;Hyuk-Soo Seo ,&nbsp;Sirano Dhe-Paganon ,&nbsp;Sara J. Buhrlage ,&nbsp;Jarrod A. Marto","doi":"10.1016/j.slasd.2024.100198","DOIUrl":null,"url":null,"abstract":"<div><div>Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for small molecule inhibitors or find new binding pockets on proteins of interest. These libraries span diverse chemical space with a modest number of compounds. Screening covalent fragments against purified protein targets reduces the demands on the mass spectrometer with respect to absolute throughput, detection limit, and dynamic range. Given these relaxed analytical requirements, we sought to develop an open-source, medium-throughput mass spectrometry system for target-based covalent fragment screening. Our platform comprises automated, dual LC desalting columns integrated with electrospray ionization for rapid sample introduction and mass spectrometry detection. The system is operated through a simple Python graphical user interface running on commodity microcontroller boards which allow integration with diverse liquid chromatography and mass spectrometry instruments. We provide scripts for fragment pooling, construction of sample batches, along with routines for data processing and visualization. The system enables primary screening of ∼10,000 covalent fragments per day in pooled format. In a proof-of-concept study we executed primary and secondary screens to identify 27 hit fragments against UCHL1, a deubiquitinating enzyme that is emerging as a drug target of interest across multiple clinical indications. We validated and triaged these covalent compounds through a series of orthogonal biochemical and chemoproteomic assays. The most promising chloroacetamide covalent fragment inhibited UCHL1 activity in vitro (IC<sub>50</sub> &lt; 5 µM) and exhibited dose-dependent binding along with good selectivity against 57 cellular DUBs as quantified by activity-based protein profiling.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100198"},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors\",\"authors\":\"Scott B. Ficarro ,&nbsp;Zachary H. Marto ,&nbsp;Nicholas M. Girardi ,&nbsp;Dingyu Deng ,&nbsp;Isabella Jaen Maisonet ,&nbsp;Guillaume Adelmant ,&nbsp;Laura E. Fleming ,&nbsp;Mona Sharafi ,&nbsp;Isidoro Tavares ,&nbsp;Andrew Zhao ,&nbsp;HyoJeon Kim ,&nbsp;Hyuk-Soo Seo ,&nbsp;Sirano Dhe-Paganon ,&nbsp;Sara J. Buhrlage ,&nbsp;Jarrod A. Marto\",\"doi\":\"10.1016/j.slasd.2024.100198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for small molecule inhibitors or find new binding pockets on proteins of interest. These libraries span diverse chemical space with a modest number of compounds. Screening covalent fragments against purified protein targets reduces the demands on the mass spectrometer with respect to absolute throughput, detection limit, and dynamic range. Given these relaxed analytical requirements, we sought to develop an open-source, medium-throughput mass spectrometry system for target-based covalent fragment screening. Our platform comprises automated, dual LC desalting columns integrated with electrospray ionization for rapid sample introduction and mass spectrometry detection. The system is operated through a simple Python graphical user interface running on commodity microcontroller boards which allow integration with diverse liquid chromatography and mass spectrometry instruments. We provide scripts for fragment pooling, construction of sample batches, along with routines for data processing and visualization. The system enables primary screening of ∼10,000 covalent fragments per day in pooled format. In a proof-of-concept study we executed primary and secondary screens to identify 27 hit fragments against UCHL1, a deubiquitinating enzyme that is emerging as a drug target of interest across multiple clinical indications. We validated and triaged these covalent compounds through a series of orthogonal biochemical and chemoproteomic assays. The most promising chloroacetamide covalent fragment inhibited UCHL1 activity in vitro (IC<sub>50</sub> &lt; 5 µM) and exhibited dose-dependent binding along with good selectivity against 57 cellular DUBs as quantified by activity-based protein profiling.</div></div>\",\"PeriodicalId\":21764,\"journal\":{\"name\":\"SLAS Discovery\",\"volume\":\"29 8\",\"pages\":\"Article 100198\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SLAS Discovery\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2472555224000601\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Discovery","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2472555224000601","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

基于靶标的共价片段文库筛选与质谱已经成为一种强大的策略,以确定小分子抑制剂的化学起点或在感兴趣的蛋白质上找到新的结合口袋。这些文库跨越不同的化学空间,包含少量的化合物。针对纯化蛋白目标筛选共价片段减少了对质谱仪在绝对通量、检测限和动态范围方面的需求。鉴于这些宽松的分析要求,我们寻求开发一种开源的、中等通量的质谱系统,用于基于靶标的共价片段筛选。我们的平台包括自动化,双LC脱盐柱集成电喷雾电离快速样品导入和质谱检测。该系统通过一个简单的python图形用户界面运行在商品微控制器板上,允许与各种液相色谱和质谱仪器集成。我们提供了用于片段池、构建样本批次的脚本,以及用于数据处理和可视化的例程。该系统能够以混合格式每天对~ 10,000个共价片段进行初步筛选。在一项概念验证研究中,我们进行了一次和二次筛选,以确定27个针对UCHL1的命中片段,UCHL1是一种去泛素化酶,正在成为多种临床适应症中感兴趣的药物靶点。我们通过一系列正交生化和化学蛋白质组学分析验证和分类这些共价化合物。最有希望的氯乙酰胺共价片段体外抑制UCHL1活性(IC50)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors
Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for small molecule inhibitors or find new binding pockets on proteins of interest. These libraries span diverse chemical space with a modest number of compounds. Screening covalent fragments against purified protein targets reduces the demands on the mass spectrometer with respect to absolute throughput, detection limit, and dynamic range. Given these relaxed analytical requirements, we sought to develop an open-source, medium-throughput mass spectrometry system for target-based covalent fragment screening. Our platform comprises automated, dual LC desalting columns integrated with electrospray ionization for rapid sample introduction and mass spectrometry detection. The system is operated through a simple Python graphical user interface running on commodity microcontroller boards which allow integration with diverse liquid chromatography and mass spectrometry instruments. We provide scripts for fragment pooling, construction of sample batches, along with routines for data processing and visualization. The system enables primary screening of ∼10,000 covalent fragments per day in pooled format. In a proof-of-concept study we executed primary and secondary screens to identify 27 hit fragments against UCHL1, a deubiquitinating enzyme that is emerging as a drug target of interest across multiple clinical indications. We validated and triaged these covalent compounds through a series of orthogonal biochemical and chemoproteomic assays. The most promising chloroacetamide covalent fragment inhibited UCHL1 activity in vitro (IC50 < 5 µM) and exhibited dose-dependent binding along with good selectivity against 57 cellular DUBs as quantified by activity-based protein profiling.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
SLAS Discovery
SLAS Discovery Chemistry-Analytical Chemistry
CiteScore
7.00
自引率
3.20%
发文量
58
审稿时长
39 days
期刊介绍: Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology. SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).
期刊最新文献
A secretome screen in primary human lung fibroblasts identifies FGF9 as a novel regulator of cellular senescence Corelet™ platform: Precision high throughput screening for targeted drug discovery of biomolecular condensates Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids A novel high-throughput screening platform to identify inhibitors of DNAJB1-PRKACA-driven transcriptional activity in fibrolamellar carcinoma Comparative evaluation of cell-based assay technologies for scoring drug-induced condensation of SARS-CoV-2 nucleocapsid protein
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1